Originally posted by krobison
View Post
I understand your point about psedoautosomal regions and not being terribly useful for tracing the male lineage. When I started this thread it was not clear to me if there were viable methods to separate chromosomes for sequencing from the whole genome without full genome sequencing. Again I am not an expert and have no experience in sequencing machines and there use.
So far I have discovered that methods do exist.
1. The 1000 genomes project is using a method for separating the chromosomes
2. There are flow shorter machines that separate chromosomes.
3. In this article there is Fluorescence activated cell sorting technology
4. Illumina Inc. also uses a process for separating the chromosomes in their whole genome sequencing.
The process for sorting of the chromosomes and sequencing machines are in the market place today. Is there a business model that meets a commercial need that people will pay for that can sustain a viable commercial business? My personal answer to this is yes. I have stated earlier in this thread about the numbers and why people would be interested in this kind of testing.
Let me give you examples of the market place dictating new products. Until companies such as Decodeme and 23andme a genealogy company such as Familytreedna had no interest in autosomal tests on chips. Because of the success in the market place today of the 23andme product Familytreedna has their own chip and test for this now. Ethnoancestry was first to the market place for the testing of individual snp’s. Again the market demand made Familytreedna create products for this kind of testing.
I believe that sequencing companies today are so focused on health issues, animal husbandry, and agriculture advances in genome testing that the market place I describe is not even given consideration. It may be niche market. But I think it is a moneymaking niche market not on the scale of these other markets but still a large market in its own right.
I have seen no indication as of yet that sequencing the Y would fall under the regulations of the CLIA certification at this point in time. Just a side note, I have had a telephone conversation with an Associate at Illumina Inc. who will get back to me after the new year when he has had time to discuss this idea with his company. They have not thrown me under the bus as of yet with this concept.
In a perfect world it would be a swab or spit test for the sample. If it requires blood for the process we can live with that. We must first get the sequence. Then the second part to this equation is the library and other software to complement and compare the results.
Comment